Close

bluebird bio (BLUE) LentiGlobin 'Does Work', Maxim Group Says

November 5, 2015 1:06 PM EST Send to a Friend
Maxim Group analyst Jason McCarthy reiterated a Buy rating and $190 price target on bluebird bio (NASDAQ: BLUE) following today's ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login